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OBJECTIVE—Diabetic impaired angiogenesis is associated
with impairment of hypoxia-inducible factor-1 (HIF-1) as well
as vasculature maturation. We investigated the potential roles
and intracellular mechanisms of angiopoietin-1 (Ang-1) gene
therapy on myocardial HIF-1 stabilization and vascular matura-
tion in db/db mice.
RESEARCH DESIGN AND METHODS—db/db mice were sys-
temically administrated adenovirus Ang-1 (Ad-CMV-Ang-1). Myo-
cardial HIF-1, vascular endothelial growth factor (VEGF),
hemeoxygenase-1 (HO-1), endothelial nitric oxide synthase
(eNOS), Akt, and HIF-1–prolyl-4-hydroxylase-2 (PHD)2 expres-
sion were measured. Vasculature maturation, capillary and arte-
riole densities, and cardiac interstitial ﬁbrosis were analyzed in
the border zone of infarcted myocardium.
RESULTS—Systemic administration of Ad-CMV-Ang-1 results in
overexpression of Ang-1 in db/db mice hearts. Ang-1 gene therapy
causes a signiﬁcant increase in Akt and eNOS expression and
HIF-1 stabilization. This is accompanied by a signiﬁcant upregu-
lation of VEGF and HO-1 expression. Intriguingly, Ang-1 gene
therapy also leads to a signiﬁcant inhibition of PHD2 expression.
Smooth muscle recruitment and smooth muscle coverage in the
neovessels of the border zone of infarcted myocardium are
severely impaired in db/db mice compared with wild-type mice.
Ang-1 gene therapy rescues these abnormalities, which leads to a
dramatic increase in capillary and arteriole densities and a
signiﬁcant reduction of cardiac hypertrophy and interstitial ﬁbro-
sis at 14 days after ischemia. Taken together, our data show that
Ang-1 increases myocardial vascular maturation and angiogene-
sis together with suppression of PHD2 and the upregulation of
HIF-1 signaling.
CONCLUSIONS—Normalization of immature vasculature by
Ang-1 gene therapy may represent a novel therapeutic strategy
for treatment of the diabetes-associated impairment of myocar-
dial angiogenesis. Diabetes 57:3335–3343, 2008
A
ngiogenesis is mainly regulated by the interplay
between two receptor tyrosine kinase families,
speciﬁcally, the vascular endothelial growth fac-
tor (VEGF)/VEGF receptor (VEGFR) and angio-
poietins/Tie-2 families (1,2). Similar to VEGF/VEGFR, Tie-2 is
an endothelial-speciﬁc receptor tyrosine kinase predomi-
nantly expressed in the vascular endothelium. Ang-1 is an
oligomeric-secreted glycoprotein that binds to the Tie-2
receptor and induces Tie-2 phosphorylation (3–5). Accu-
mulating data demonstrate that dominant Ang-1/Tie-2 sig-
naling is essential for the maintenance of endothelial
integrity and vessel maturation (3,5–10). VEGF is required
to initiate immature vascular formation, whereas Ang-1 is
required for further remodeling and maturation of VEGF-
initiated immature vessels during postischemic angiogen-
esis (1,2). Overexpression of Ang-1 in transgenic mice
leads to larger and more mature neovessel formation (5).
Myocardial ischemia-induced angiogenesis is regulated
by hypoxia-inducible factor-1 (HIF-1) and VEGF. The
expression of HIF-1 and VEGF is signiﬁcantly increased
in the human heart during ischemia, which may contribute
to the limitation of ischemic injury by promoting angio-
genesis and collateral vessel formation (11). However, the
expression of both HIF-1 and VEGF is signiﬁcantly
decreased in diabetic patients (12). Similarly, in the strep-
tozotocin-induced diabetic animal model, myocardial isch-
emia/reperfusion–induced HIF-1 expression is impaired,
indicating a critical role of hyperglycemia in HIF-1 stabi-
lization and the impairment of angiogenesis (13). So far,
the intracellular molecular mechanisms by which hyper-
glycemia decreases HIF-1 expression have not been
identiﬁed. It is well known that HIF-1 is regulated by
HIF-1-prolyl-4-hydroxylases (PHDs), which target HIF-1
for ubiquitination and proteasomal degradation (14–16).
Most recent research demonstrates that nitric oxide (NO)
inhibits PHD2 activity and increases HIF-1 accumulation
(17). In a previous study, we demonstrated that Ang-1 is an
important component in regulating coronary artery endo-
thelial NO production and that Ang-1 mediates myocardial
angiogenesis in endothelial NO synthase (eNOS)/NO-de-
pendent mechanisms (18). In the present study, we test
whether Ang-1 gene therapy rescues defective HIF-1
signaling and improves impaired myocardial angiogenesis
by the inhibition of PHD2 in type 2 diabetic db/db mice.
RESEARCH DESIGN AND METHODS
Experimental diabetic mouse myocardial ischemia model. C57BLKS/J
and db/db mice (12–14 weeks of age) were purchased from The Jackson
Laboratories (Bar Harbor, ME). Experimental mice were anesthetized with
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DIABETES, VOL. 57, DECEMBER 2008 3335ketamine (100–120 mg/kg) plus xylazine (15 mg/kg), intubated, and artiﬁcially
ventilated with room air. A left thoracotomy was performed, and the left
anterior descending coronary artery (LAD) was exposed. An 8-O nylon suture
was placed around the LAD. Myocardial ischemia was achieved by ligation of
the LAD. The sham control underwent the surgery without the LAD ligation
(19–21).
Systemic delivery of Ang-1 in experimental mice. After the surgery, db/db
mice received an intravenous tail vein injection of Ad-Ang-1 (1  10
9
plaque-forming units [Pfu]) or Ad--gal (1  10
9 Pfu) (21).
Blood glucose and Ang-1 levels. Blood was obtained from db/db and
Ad-Ang-1–treated db/db mice by tail snip, and blood glucose levels were
measured with the use of One Touch SureStep test strips and a meter. Glucose
levels are expressed as milligrams per deciliter. The serum Ang-1 level was
measured with an Ang-1 immunoassay kit (R&D Systems, Minneapolis, MN).
Analysis of Ang-1, PHD2, hemeoxygenase-1, eNOS, Akt, HIF-1, and
VEGF expression. At 24 h after myocardial ischemia, the hearts were
harvested and homogenized in lysis buffer. Fifty micrograms of total protein
were separated using SDS gel electrophoresis. The membranes were immu-
noblotted with HIF-1 (1:1,000; GeneTex, San Antonio, TX), hemeoxygenase
(HO)-1 and eNOS (1:1,000; BD Transduction Laboratories, San Jose, CA), Akt
(1:1,000; Cell Signaling Techology, Danvers, MA), PHD2, VEGF, and Ang-1
antibodies (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA). For the liver
Ang-1 expression, the membrane was immunoblotted with monoclonal anti–
Ang-1 (1:1,000, Sigma, St. Louis, MO).
Analysis of myocardial capillary and arteriole densities. At 14 days after
myocardial ischemia, the hearts were harvested and ﬂash frozen immediately
in SUPER FRIENDLY FREEZE’IT (Fisher, TX). Five-micrometer sections
were cut and incubated with ﬂuorescerin-labeled Griffonia Bandeiraea Sim-
plicifolia Isolectin B4 (1:200; LB4, Molecular Probe, Invitrogen, Eugene, OR)
and Cy3-conjugated anti- smooth muscle actin (SMA) (1:100; Sigma). The
number of capillaries (LB4-positive EC) was counted and expressed as
capillary density per square millimeter (mm
2). Myocardial arteriole (SMA-
positive smooth muscle cells located in vascular walls) density was measured
using image analysis software (Image J, National Institutes of Health, Be-
thesda, MD). To assess the acquisition of a muscular coat by infarct neoves-
sels, the density of coated neovessels in the border zone of infarcted area was
measured by using a section stained for SMA. Smooth muscle cell (SMC)/
neovessel coverage in the border zone of infarcted area was measured using
image analysis software (Image J, National Institutes of Health) (20,21).
Cardiac hypertrophy and interstitial ﬁbrosis. Cardiac hypertrophy was
assessed by measuring heart weight–to–body weight ratio. Each heart weight
at 14 days postmyocardial ischemia was divided by the total body weight of
the mouse, resulting in a ratio representative of cardiac hypertrophy. To
determine cardiac ﬁbrosis, sections were stained with Masson’s trichrome
(Sigma). Myocardial interstitial ﬁbrosis was quantiﬁed by measuring the
Masson’s trichrome staining area in the remote zone of the infarcted area
using National Institutes of Health image analysis software as previously
described (22,23).
Mouse aortic ring sprouting and SMC recruitment assay in ex vivo
model. Mouse aortas were isolated from C57BLKS/J and db/db mice under
aseptic conditions and cut into rings 1 mm in thickness. These rings were
then placed in the middle of organ culture dishes, overlaid with 300 l
extracellular matrix (Sigma), and left to polymerize for 1–2 h at 37°C before
the addition of 10% FBS endothelial growth medium. Vessel outgrowth at day
5 was examined using a Nikon TE-300 microscope. To characterize SMC
recruitment, speciﬁc endothelial cell and SMC markers were directly applied
to ex vivo aortic culture explants. Brieﬂy, the cultured explants were ﬁxed
with 10% formalin for 20 min, washed with PBS, and incubated for 3 h with the
following speciﬁc cell markers: ﬂuorescein isothiocyanate–labeled mouse
CD31 antibody (1:100, BD Biosciences, San Jose, CA) for EC and Cy3-
conjugated anti- SMA (1:100; Sigma) for SMCs. After incubation with these
cell markers, the slides were washed three times with PBS (10 min) and
mounted on an aqueous mounting medium. The immunostained explants of
aortas were examined using confocal microscopy (19,20,24–26). SMC recruit-
ment was quantiﬁed by measuring the relative area of SMC/endothelial cell
coverage using image acquisition and analysis software (Image J, National
Institutes of Health). All procedures were in conformance with the Institute
for Laboratory Animal Research Guide for the Care and Use of Laboratory
Animals and were approved by the Vanderbilt University Institutional Animal
Care and Use Committee.
Statistical analysis. The results are expressed as the mean  SD. Statistical
analysis was performed using ANOVA followed by a t test corrected for
multiple comparisons (Student-Newman-Keuls). Signiﬁcance was set at P 
0.05.
RESULTS
Systemic administration of Ad-CMV-Ang-1 by a single
dose results in a sustained overexpression of Ang-1
in db/db mouse hearts. Intravenous administration of
Ad-CMV-Ang-1 (1  10
9 Pfu) in db/db mice led to viral
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FIG. 1. A: Western blot analysis demonstrating that systemic adminis-
tration of Ad-Ang-1 (1  10
9 Pfu Ad-Ang-1) resulted in overexpression
of Ang-1 in the db/db mice liver at day 1 and day 14 (n  4–5 mice). B:
Serum level of Ang-1 after intravenous Ad-Ang-1 treatment in db/db
mice. Values are expressed as mean  SD (n  6–7) mice. C: Systemic
delivery of Ad-Ang-1 in db/db mice led to a gradual decrease in glucose
levels compared with Ad--gal–treated db/db mice during 14 days of
the studies (n  6) (*P < 0.05). D: Western blot analysis showing that
myocardial Ang-1 protein expression was signiﬁcantly increased at day
1 and remained elevated for 14 days in db/db mice after the systemic
delivery of Ad-Ang-1. WT, wild type.
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liver started to increase at day 1, and the increase lasted
for 2 weeks after intravenous administration of one bolus
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FIG. 2. A: Representative Western blot and densitometry analyses of
myocardial HIF-1 expression. Myocardial HIF-1 expression was
diminished in db/db mice compared with wild-type mice (WT). Overex-
pression of Ang-1 signiﬁcantly enhanced HIF-1 expression in db/db
mice at the basal level and under ischemic conditions (n  6 mice). B:
Myocardial ischemia–induced VEGF expression was blunted in db/db
mice compared with wild-type mice following myocardial ischemia.
Overexpression of Ang-1 resulted in a signiﬁcant increase in VEGF
expression (n  6). C: Western blot analysis showing that wild-type
mice subjected to ischemia for 24 h demonstrated a signiﬁcant increase
in HO-1 expression; myocardial ischemia failed to induce HO-1 expres-
sion in diabetic db/db mice. Systemic delivery of Ad-Ang-1 led to a
signiﬁcant increase in HO-1 expression in db/db mouse hearts (n  6).
*P < 0.05. IS, ischemia; WT, wild type.
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FIG. 3. Representative Western blot analysis of myocardial Akt and
eNOS expression in wild-type, db/db, and Ad-Ang-1–treated db/db
mice. A: eNOS protein expression was diminished in db/db mouse
hearts, whereas overexpression of Ang-1 resulted in a signiﬁcant
increase in eNOS protein expression (Western blot data represented
by four independent experiments). B: Total Akt protein expression
was reduced in db/db mice compared with wild-type mice at the
baseline level and at 24 h after myocardial ischemia. Systemic delivery
of Ad-Ang-1 resulted in a signiﬁcant increase in Akt expression in
db/db mice. This increase was not observed in db/db mice treated with
Ad--gal (Western blot data represented by six independent experi-
ments). C: Representative Western blot and densitometry analyses of
myocardial PHD2 protein expression at 24 h after myocardial ischemia.
Western blot analysis showing decreased PHD2 expression in wild-type
mice subjected to myocardial ischemia for 24 h. In db/db mice, basal
PHD2 expression was increased without any further increase following
myocardial ischemia. Systemic delivery of Ad-Ang-1 resulted in a
signiﬁcant decrease in PHD2 expression in db/db mice (n  6). *P <
0.05. IS, ischemia; WT, wild type.
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DIABETES, VOL. 57, DECEMBER 2008 3337of Ad-CMV-Ang-1 (Fig. 1A). Similarly, the serum level of
Ang-1 was increased 1 day after the Ad-CMV-Ang-1 injec-
tion and remained at the elevated level for 2 weeks in
diabetic db/db mice (Fig. 1B). Intriguingly, glucose levels
were signiﬁcantly decreased in Ad-Ang-1–treated db/db
mice during 14 days of the study (Fig. 1C). To further
examine whether systemic administration of Ad-CMV-
Ang-1 results in overexpression of Ang-1 in the heart, we
examined myocardial Ang-1 levels in db/db mice. Our
Western blot analysis data showed that myocardial Ang-1
protein expression was signiﬁcantly increased at day 1 and
remained elevated for 14 days in db/db mice after the
systemic delivery of Ad-Ang-1 (Fig. 1D). Additionally, we
conducted ﬂuorescent immunohistochemistry and confo-
cal imaging to discern the location of Ang-1 expression in
Ad-Ang-1–treated db/db mouse hearts. Our merged images
revealed that Ang-1 localized with Isolectin B4 (LB4) on
ECs and SMA on vessel SMCs (supplemental Fig. 1 in the
online appendix available at http://dx.doi/org/10.2337/
db08-0503).
Ang-1 gene therapy stabilizes HIF-1 expression and
rescues impaired HIF-1 signaling in response to
ischemia in db/db mice. Our Western blot analysis
revealed that wild-type mouse hearts exposed to ischemia
for 24 h resulted in a signiﬁcant increase in HIF-1
expression, whereas myocardial ischemia-induced HIF-1
expression was signiﬁcantly blunted in db/db mouse hearts
(Fig. 2A). Diabetic db/db mice treated with Ad-Ang-1
showed a signiﬁcant increase in HIF-1 expression after
myocardial ischemia compared with db/db mice that re-
ceived the control vector (Fig. 2A). Next, we examined the
expression of the HIF-1 downstream angiogenic signaling
molecules VEGF and HO-1 in response to myocardial
ischemia in db/db mice. Wild-type mouse hearts subjected
to ischemia for 24 h experienced a signiﬁcant increase in
both VEGF and HO-1 expression. Myocardial ischemia-
induced VEGF and HO-1 expression was diminished in
db/db mouse hearts subjected to ischemia for 24 h (Fig. 2B
and C). Systemic administration of Ad-Ang-1 resulted in a
signiﬁcant increase in VEGF and HO-1 expression in db/db
mice (Fig. 2B and C). Our colocalization immunohisto-
chemical studies revealed that HIF-1 expression, but not
VEGF, was colocalized with Tie-2 (supplemental Fig. 2).
Furthermore, Ang-1 was colocalized to only a small extent
with VEGF and HO-1 in Ad-Ang-1–treated db/db mouse
hearts (supplemental Fig. 3). These data suggested that
other mechanisms may be involved in regulation of VEGF
and HO-1 expression in Ad-Ang-1–treated db/db mice.
Ang-1 upregulates eNOS and Akt and downregulates
PHD2 expression. To explore the potential intracellular
molecular mechanism by which overexpression of Ang-1
rescues the impaired HIF-1 signaling in diabetes, myocar-
dial eNOS, Akt, and PHD2 expression in db/db mice was
examined. Myocardial eNOS and Akt expression was signif-
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area of CD31/SMC coverage demonstrating that smooth muscle recruitment was signiﬁcantly reduced in db/db mouse aortic ring explants.
Systemic delivery of Ad-Ang-1 resulted in a signiﬁcant increase in SMC recruitment in db/db mouse aortic ring explants (n  6 mice). *P < 0.05.
WT, wild type. (Please see http://dx.doi.org/10.2337/db08-0503 for a high-quality digital representation of this ﬁgure.)
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emia compared with hearts from wild-type mice. Systemic
delivery of Ad-Ang-1 strikingly increased eNOS and Akt
expression (Fig. 3A and B). This was accompanied by a
signiﬁcant suppression of PHD2 protein expression in db/db
mice under both basal and ischemic conditions (Fig. 3C).
Overexpression of Ang-1 increases smooth muscle
recruitment and improves myocardial ischemia-in-
duced vasculature maturation. Using the ex vivo aortic
ring sprouting explants model, we ﬁrst examined whether
overexpression of Ang-1 rescues impaired SMC recruit-
ment in db/db mice. As shown in Fig. 4A and B, SMC
coverage was signiﬁcantly less in aortic ring explants
isolated from db/db mice than in those from wild-type
mice. Overexpression of Ang-1 signiﬁcantly increased
SMC recruitment in db/db mouse aortic ring explants (Fig.
4A and B).
Our morphological analysis further showed that the
border zone of infarcted myocardial area contained a
signiﬁcant number of mature, coated neovessels in wild-
type mice subjected to myocardial ischemia, whereas few
coated neovessels were found in db/db mouse hearts after
14 days of ischemia (Fig. 5A). Overexpression of Ang-1
signiﬁcantly increased the number of mature, coated
neovessels in db/db mice (Fig. 5A). To further identify
whether overexpression of Ang-1 improves myocardial
smooth muscle recruitment, the relative ratio of SMA to
neovessel coverage in the border zone of infarcted myo-
cardial area was investigated in db/db mouse hearts after
14 days of ischemia. In the border zone of infarcted
myocardial area of wild-type mice, 71.9% of the neovessels
were stained positive for SMA after 14 days of myocardial
ischemia. The relative ratio of SMC to neovessel coverage
was considerably reduced, and only 21.8% of neovessels
were covered with SMA in the db/db mouse hearts. Over-
expression of Ang-1 resulted in a signiﬁcant increase in the
ratio of SMC to neovessel coverage in the db/db mouse
hearts (Fig. 5B).
Overexpression of Ang-1 increases myocardial isch-
emia-induced capillary and arteriole densities. To
investigate whether overexpression of Ang-1 in db/db
diabetic mouse hearts improves myocardial angiogenesis
in vivo, myocardial capillary and arteriole densities in the
border zone of infarcted myocardial area were examined
at 14 days after myocardial ischemia. Our immunohisto-
chemical studies revealed that overexpression of Ang-1 in
db/db mouse hearts resulted in a signiﬁcant increase in
myocardial capillary density in the border zone of in-
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Furthermore, the number of arterioles in the healing
myocardium was also signiﬁcantly increased compared
with the Ad--gal–treated db/db mice (Fig. 6B).
Overexpression of Ang-1 attenuates cardiac hyper-
trophy and interstitial ﬁbrosis. The heart weight–to–
body weight ratio and myocardial interstitial ﬁbrosis were
evaluated to further investigate the consequence of Ad-
Ang-1–induced vasculature maturation and angiogenesis
on cardiac remodeling. The heart weight–to–body weight
ratio was measured at 14 days after myocardial ischemia.
As shown in Fig. 7A, myocardial ischemia resulted in a
signiﬁcant increase in the heart weight–to–body weight
ratio in db/db mice compared with wild-type mice. Treat-
ment with Ad-Ang-1 led to a 27% decrease in the heart
weight–to–body weight ratio in db/db mice subjected to
myocardial ischemia (Fig. 7A). Myocardial ﬁbrosis was
signiﬁcantly increased in db/db mice compared with wild-
type mice after myocardial ischemia (Fig. 7B and C).
Myocardial interstitial ﬁbrosis in the remote zone was
signiﬁcantly reduced in Ad-Ang-1–treated db/db mice com-
pared with Ad--gal–treated db/db mice at 14 days after
myocardial ischemia (Fig. 7B and C).
DISCUSSION
The novel ﬁndings of our present studies reveal that: 1)
overexpression of Ang-1 stabilizes HIF-1 protein expres-
sion and rescues impaired endogenous angiogenic growth
factors in db/db mouse hearts subjected to myocardial
ischemia; 2) overexpression of Ang-1 leads to a signiﬁcant
increase in eNOS and Akt expression and the suppression
of PHD2 expression; 3) overexpression of Ang-1 promotes
SMC recruitment, normalizes immature vasculature, and
increases mature neovessel formation, which is accompa-
nied by a signiﬁcant improvement in ischemia-induced
capillary and arteriole densities in the border zone of the
infarcted area of db/db mouse hearts; and 4) overexpres-
sion of Ang-1 reduces myocardial ischemia-induced car-
diac hypertrophy and interstitial ﬁbrosis. Our data strongly
suggest that Ang-1 gene therapy promotes vascular matu-
ration and stabilization and rescues impaired myocardial
angiogenesis and myocardial remodeling via a mechanism
involving the suppression of PHD2 and the upregulation of
HIF-1 signaling.
HIF-1 is a transcriptional activator that is expressed in
response to hypoxia and ischemia (27,28). HIF-1 has
been shown to bind to a hypoxia-response element and to
regulate VEGF expression (28,29). Recent studies demon-
strate that hyperglycemia impairs HIF-1 and VEGF ex-
pression in human microvascular ECs and rat proximal
tubule cells (30,31). Furthermore, defective hypoxic sig-
naling and the loss of HIF expression have been shown to
contribute to the dysfunction of pancreatic -cells in
diabetic patients (32). Recent research shows that the
inhibition of PHD2 with small interfering RNA (siRNA)
protects against ischemia/reperfusion-induced myocardial
injury (33). Most recent research also demonstrates that
the deﬁciency of PHD2 promotes the formation of mature
new blood vessels in mouse hearts (34). These data raise the
possibility that PHD2 may be a novel therapeutic target for
the treatment of diabetic impaired HIF-1 signaling and the
impairment of angiogenesis. Our present studies demon-
strate for the ﬁrst time that overexpression of Ang-1 sup-
presses PHD2 expression and attenuates myocardial
ischemia-induced impairment of HIF-1 signaling and its
downstream VEGF and HO-1 expression in db/db mice.
Further studies are needed to test whether the inhibition of
PHD2 activity by using PHD2 siRNA could rescue HIF-1
signaling and improve impaired angiogenesis in diabetes.
Our present studies clearly demonstrate that Ang-1
stabilizes HIF-1 protein expression and suppresses PHD2
expression; however, the intracellular mechanism by
which Ang-1 mediates this effect in diabetic hearts still
remains unknown. NO has been shown to regulate HIF-1
expression and activity under normoxic conditions. Re-
cent studies also reveal that NO donors or the increase of
NO formation promotes HIF-1 stabilization and increases
VEGF gene expression. Furthermore, both NO-induced
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FIG. 6. A: Representative quantitative analysis by LB4 staining showing that, in Ad--gal–treated db/db mice, myocardial ischemia–induced
myocardial capillary density was signiﬁcantly decreased compared with that of wild-type mice. Treatment with Ad-Ang-1 signiﬁcantly increased
capillary formation in db/db mice subjected to ischemia (n  6). B: Representative quantitative analysis by SMC staining showing that myocardial
ischemia–induced arteriole density was reduced in Ad--gal–treated db/db mice compared with wild-type mice subjected to myocardial ischemia
for 14 days. Treatment with Ad-Ang-1 caused a greater increase in arteriole formation in db/db mice subjected to ischemia than treatment with
Ad--gal (n  6). *P < 0.05. IS, ischemia; WT, wild type.
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NO-dependent inhibition of PHD activity (17,37) have been
shown to contribute to HIF-1 stabilization. Additionally,
Ang-1 gene transfer has been shown to increase eNOS
expression and reverse pulmonary hypertension (38).
Ang-1 gene transfer has also been reported to prevent
diabetic retinal vascular changes and to attenuate the
increased retinal permeability by the upregulation of eNOS
expression in the streptozotocin-induced diabetic rat
model (39). Consistent with these ﬁndings, our Western
blot analysis also shows that eNOS and Akt protein
expression was attenuated in db/db mice hearts. Ang-1
gene therapy results in an approximately twofold increase
in eNOS and Akt protein expression in the hearts of db/db
mice, indicating that Ang-1 might inhibit PHD2 and stabi-
lize HIF-1 protein by a mechanism involving the upregu-
lation of Akt and eNOS expression.
Ang-1 is an important vascular stabilizing factor that
controls SMC recruitment and neovessel maturation. Al-
though VEGF initiates neovessel formation during tissue
ischemia, Ang-1 promotes subsequent remodeling, matu-
ration, and stabilization (4,5). During the progression of
myocardial ischemia, the neovessels of the ischemic area
acquire a muscular coat to form a mature vasculature and
stabilize the myocardium, whereas uncoated neovessels
undergo regression (40–42). Therefore, the recruitment of
SMC is crucial for the growth of mature neovessels and the
prevention of neovessel regression (43). Abnormal dia-
betic angiogenesis is characterized by both structural and
functional derangements, and diabetic neovessels are
leaky, tortuous, and immature. These structural abnormal-
ities may cause or contribute to many of the clinical
manifestations of diabetes. Our previous studies show that
disruption of Ang-1 and Tie-2 signaling has been attributed
to the impairment of myocardial angiogenesis in diabetes
(20,21). Our data demonstrated that SMC recruitment and
myocardial ischemia-induced neovessel maturation were
severely impaired in db/db mice, implicating that the
formation of immature neovessels might be novel mecha-
nisms responsible for reduced myocardial angiogenesis
in diabetes (20). This notion was further validated by
our present data that overexpression of Ang-1 signiﬁ-
cantly increases SMC recruitment, normalizes diabetic
immature vasculature, and improves ischemia-induced
capillary and arteriole formation in diabetic db/db
mouse hearts.
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FIG. 7. A: Heart weight–to–body weight (HW/BW) ratio in wild-type, db/db, and Ad-Ang-1–treated db/db mouse hearts at 14 days after myocardial
ischemia. Cardiac hypertrophy was determined by measuring the heart weight–to–body weight ratio. Signiﬁcant increases in cardiac hypertrophy
were observed in db/db diabetic mice after 14 days of ischemia. Treatment with Ad-Ang-1 signiﬁcantly attenuated myocardial ischemia–induced
cardiac hypertrophy in db/db mouse hearts (n  6). B and C: Representative images of Masson’s trichrome staining and quantitative analysis of
myocardial interstitial ﬁbrosis of heart sections. Myocardial interstitial ﬁbrosis in the remote zone was signiﬁcantly increased in db/db mice
compared with wild-type mice at 14 days after myocardial ischemia. Myocardial interstitial ﬁbrosis was signiﬁcantly reduced in Ad-Ang-1–treated
mice compared with Ad--gal–treated db/db mice (n  6). IS, ischemia; WT, wild type. (Please see http://dx.doi.org/10.2337/db08-0503 for a
high-quality digital representation of this ﬁgure.)
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that occur in response to myocardial ischemia are known
to increase the risk of heart failure in diabetes (22,23,44).
Agents that promote angiogenesis have been shown to be
beneﬁcial to cardiac remodeling after chronic myocardial
ischemia (22,23,44). Most recent studies have demonstrated
that the systemic administration of Ang-1 signiﬁcantly re-
duced cardiac hypertrophy and myocardial ﬁbrosis in phen-
ylephrine-induced cardiac hypertrophy (45). Furthermore,
overexpression of Ang-1 decreased transforming growth
factor-1 expression and attenuated interstitial ﬁbrosis pro-
gression in the kidneys of db/db mice (46). Consistent with
these ﬁndings, our present study showed that Ang-1 gene
therapy resulted in signiﬁcant decreases in both myocardial
ﬁbrosis and in the heart weight–to–body weight ratio (hyper-
trophy) following myocardial ischemia in db/db mice, impli-
cating the favorable effects of Ang-1 gene therapy on
myocardial ischemia-induced adverse remodeling. So far, the
intracellular molecular mechanisms responsible for these
alterations and whether such alterations are associated with
reduction of myocardial transforming growth factor-1 ex-
pression in diabetes remain unknown. Additionally, our data
demonstrated that the systemic administration of Ad-Ang-1
led to a dramatic increase in the serum level of Ang-1; this
was accompanied by a signiﬁcantly lower fasting blood
glucose level in db/db mice, suggesting the metabolic effect of
Ad-Ang-1 in diabetes. Although our present studies have
focused on the intracellular mechanisms and therapeutic
potential of Ad-Ang-1 on diabetic myocardial angiogenesis
and remodeling, the metabolic effects of Ang-1 may also play
a critical role in its cardioprotective effects. The metabolic
effects resulting from the systemic administration of Ad-
Ang-1 in diabetic mice and the exact mechanisms responsi-
ble for these effects warrant further investigation. Previous
studies have demonstrated that the intravenous administra-
tion of Ad-Ang-1 in normal mice led to speciﬁc viral gene
uptake and expression in the liver, resulting in very high
circulating levels of Ang-1 for several weeks (8). Our ﬁnding
that the systemic administration of Ad-Ang-1 in diabetic
db/db mice started to increase Ang-1 production at day 1 but
caused no change at day 14 in the mouse liver, serum, and
myocardium was somewhat surprising, suggesting that
pathological conditions such as diabetes may inﬂuence viral
gene uptake and Ang-1 expression.
In summary, our present data demonstrate that myocar-
dial ischemia-induced HIF-1 expression is signiﬁcantly
decreased in db/db mouse hearts; this is accompanied by a
signiﬁcant impairment of VEGF and HO-1 expression and
vascular maturation. Overexpression of Ang-1 increases
Akt and eNOS expression and inhibits PHD2 expression,
thus leading to HIF-1 stabilization and the improvement
of immature vasculature, and rescues the impairment of
angiogenesis in diabetes. Based upon these ﬁndings, we
propose the novel concept that diabetic impaired angio-
genesis is not only caused by impaired neovessel growth
but is involved in the formation of immature vasculature,
which may result in neovessel regression. Therefore, we
propose to treat diabetic abnormal angiogenesis by nor-
malizing and stabilizing immature vasculature, thereby
preventing neovessel destabilization and regression.
ACKNOWLEDGMENTS
This work was supported by American Heart Association
Grant 0565196B and National Institutes of Health Grant
DK074995 to J.-X.C.
REFERENCES
1. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag
D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth
in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998,
1999
2. Holash J, Wiegand SJ, Yancopoulos GD: New model of tumor angiogenesis:
dynamic balance between vessel regression and growth mediated by
angiopoietins and VEGF. Oncogene 18:5356–5362, 1999
3. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE,
Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD: Isolation of
Ang-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.
Cell 87:1161–1169, 1996
4. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato
TN, Yancopoulos GD: Requisite role of Ang-1, a ligand for the TIE2
receptor, during embryonic angiogenesis. Cell 87:1171–1180, 1996
5. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato
TN, Yancopoulos GD: Increased vascularization in mice overexpressing
Ang-1. Science 282:468–471, 1998
6. Aplin AC, Gelati M, Fogel E, Carnevale E, Nicosia RF: Ang-1 and vascular
endothelial growth factor induce expression of inﬂammatory cytokines
before angiogenesis. Physiol Genomics 27:20–28, 2006
7. Daly C, Wong V, Burova E, Wei Y, Zabski S, Grifﬁths J, Lai KM, Lin HC, Ioffe
E, Yancopoulos GD, Rudge JS: Ang-1 modulates endothelial cell function
and gene expression via the transcription factor FKHR (FOXO1). Genes
Dev 18:1060–1071, 2004
8. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash
J, McDonald DM, Yancopoulos GD: Ang-1 protects the adult vasculature
against plasma leakage. Nat Med 6:460–463, 2000
9. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G,
Papapetropoulos A: Angiopoietin-2 causes inﬂammation in vivo by pro-
moting vascular leakage. J Pharmacol Exp Ther 314:738–744, 2005
10. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale
NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner
KT, Vajkoczy P, Augustin HG: Angiopoietin-2 sensitizes EC to TNF-alpha
and has a crucial role in the induction of inﬂammation. Nat Med 12:235–
239, 2006
11. Wang Y, Gabrielsen A, Lawler PR, Paulsson-Berne G, Steinbruchel DA,
Hansson GK, Kastrup J: Myocardial gene expression of angiogenic factors
in human chronic ischemic myocardium: inﬂuence of acute ischemia/
cardioplegia and reperfusion. Microcirculation 13:187–197, 2006
12. Marfella R, Esposito K, Nappo F, Siniscalchi M, Sasso FC, Portoghese M,
Di Marino MP, Baldi A, Cuzzocrea S, Di FC, Barboso G, Baldi F, Rossi F,
D’Amico M, Giugliano D: Expression of angiogenic factors during acute
coronary syndromes in human type 2 diabetes. Diabetes 53:2383–2391,
2004
13. Marfella R, D’Amico M, Di FC, Piegari E, Nappo F, Esposito K, Berrino L,
Rossi F, Giugliano D: Myocardial infarction in diabetic rats: role of
hyperglycaemia on infarct size and early expression of hypoxia-inducible
factor 1. Diabetologia 45:1172–1181, 2002
14. Semenza GL: Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE
2007:cm8, 2007
15. Willam C, Maxwell PH, Nichols L, Lygate C, Tian YM, Bernhardt W,
Wiesener M, Ratcliffe PJ, Eckardt KU, Pugh CW: HIF prolyl hydroxylases
in the rat: organ distribution and changes in expression following hypoxia
and coronary artery ligation. J Mol Cell Cardiol 41:68–77, 2006
16. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe
PJ, Gleadle JM: Differential function of the prolyl hydroxylases PHD1,
PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol
Chem 279:38458–38465, 2004
17. Berchner-Pfannschmidt U, Yamac H, Trinidad B, Fandrey J: Nitric oxide
modulates oxygen sensing by hypoxia-inducible factor 1-dependent induc-
tion of prolyl hydroxylase 2. J Biol Chem 282:1788–1796, 2007
18. Chen JX, Lawrence ML, Cunningham G, Christman BW, Meyrick B: HSP90
and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery
endothelium. J Appl Physiol 96:612–620, 2004
19. Chen JX, Zeng H, Tuo QH, Yu H, Meyrick B, Aschner JL: NADPH oxidase
modulates myocardial Akt, ERK1/2 activation and angiogenesis after
hypoxia/reoxygenation. Am J Physiol Heart Circ Physiol 292:H1664–
H1674, 2007
20. Chen JX, Stinnett A: Disruption of Ang-1/Tie-2 signaling contributes to the
impaired myocardial vascular maturation and angiogenesis in type II
diabetic mice. Arterioscler Thromb Vasc Biol 28:1606–1613, 2008
21. Tuo QH, Zeng H, Stinnett A, Yu H, Aschner JL, Liao DF, Chen JX: Critical
role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial
infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol
294:H2547–H2557, 2008
Ang-1 RESCUES IMPAIRED ANGIOGENESIS IN DIABETES
3342 DIABETES, VOL. 57, DECEMBER 200822. Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS, Sam
F, Ouchi N, Walsh K: Adiponectin protects against the development of
systolic dysfunction following myocardial infarction. J Mol Cell Cardiol
42:1065–1074, 2007
23. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K: Vascular
endothelial growth factor blockade promotes the transition from compen-
satory cardiac hypertrophy to failure in response to pressure overload.
Hypertension 47:887–893, 2006
24. Chen JX, Zeng H, Lawrence ML, Blackwell TS, Meyrick B: Ang-1-induced
angiogenesis is modulated by endothelial NADPH oxidase. Am J Physiol
Heart Circ Physiol 291:H1563–H1572, 2006
25. Zhu WH, Han J, Nicosia RF: Requisite role of p38 MAPK in mural cell
recruitment during angiogenesis in the rat aorta model. J Vasc Res
40:140–148, 2003
26. Kiefer FN, Munk VC, Humar R, Dieterle T, Landmann L, Battegay EJ: A
versatile in vitro assay for investigating angiogenesis of the heart. Exp Cell
Res 300:272–282, 2004
27. Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, Michiels C:
Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction.
FEBS Lett 460:251–256, 1999
28. Liu Y, Cox SR, Morita T, Kourembanas S: Hypoxia regulates vascular
endothelial growth factor gene expression in EC. Identiﬁcation of a 5
enhancer. Circ Res 77:638–643, 1995
29. Coulet F, Nadaud S, Agrapart M, Soubrier F: Identiﬁcation of hypoxia-
response element in the human endothelial nitric-oxide synthase gene
promoter. J Biol Chem 278:46230–46240, 2003
30. Katavetin P, Miyata T, Inagi R, Tanaka T, Sassa R, Ingelﬁnger JR, Fujita T,
Nangaku M: High glucose blunts vascular endothelial growth factor
response to hypoxia via the oxidative stress-regulated hypoxia-inducible
factor/hypoxia-responsible element pathway. J Am Soc Nephrol 17:1405–
1413, 2006
31. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L: Hyperglycemia
regulates hypoxia-inducible factor-1alpha protein stability and function.
Diabetes 53:3226–3232, 2004
32. Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH,
Roberson RS, Ricordi C, O’Connell PJ, Gonzalez FJ, Kahn CR: Loss of
ARNT/HIF1beta mediates altered gene expression and pancreatic-islet
dysfunction in human type 2 diabetes. Cell 122:337–349, 2005
33. Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, Fowler AA III: Hypoxia
inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing
attenuates myocardial ischemia reperfusion injury. Circ Res 98:133–140,
2006
34. Takeda K, Cowan A, Fong GH: Essential role for prolyl hydroxylase
domain protein 2 in oxygen homeostasis of the adult vascular system.
Circulation 116:774–781, 2007
35. Sandau KB, Faus HG, Brune B: Induction of hypoxia-inducible-factor 1 by
nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res
Commun 278:263–267, 2000
36. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T,
Semenza GL, Hirota K: Nitric oxide induces hypoxia-inducible factor 1
activation that is dependent on MAPK and phosphatidylinositol 3-kinase
signaling. J Biol Chem 279:2550–2558, 2004
37. Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B: Nitric oxide impairs
normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases.
Mol Biol Cell 14:3470–3481, 2003
38. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ: Protective role of Ang-1
in experimental pulmonary hypertension. Circ Res 92:984–991, 2003
39. Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y,
Bursell SE, Wiegand SJ, Rudge J, Ioffe E, Yancopoulos GD, Adamis AP:
Suppression of diabetic retinopathy with Ang-1. Am J Pathol 160:1683–
1693, 2002
40. Frangogiannis NG: The mechanistic basis of infarct healing. Antioxid
Redox Signal 8:1907–1939, 2006
41. Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S,
Michael LH, Entman ML, Frangogiannis NG: Of mice and dogs: species-
speciﬁc differences in the inﬂammatory response following myocardial
infarction. Am J Pathol 164:665–677, 2004
42. Ren G, Michael LH, Entman ML, Frangogiannis NG: Morphological char-
acteristics of the microvasculature in healing myocardial infarcts. J His-
tochem Cytochem 50:71–79, 2002
43. Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML,
Frangogiannis NG: The role of platelet-derived growth factor signaling in
healing myocardial infarcts. J Am Coll Cardiol 48:2315–2323, 2006
44. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS,
Walsh K: Disruption of coordinated cardiac hypertrophy and angiogenesis
contributes to the transition to heart failure. J Clin Invest 115:2108–2118,
2005
45. Dallabrida SM, Ismail NS, Pravda EA, Parodi EM, Dickie R, Durand EM, Lai
J, Cassiola F, Rogers RA, Rupnick MA: Integrin binding Ang-1 monomers
reduce cardiac hypertrophy. FASEB J 22:3010–3023, 2008
46. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang KY, Lee SY, Park
BH, Koh GY, Park SK: Renoprotective effect of COMP-Ang-1 in db/db mice
with type 2 diabetes. Nephrol Dial Transplant 22:396–408, 2007
J.-X. CHEN AND A. STINNETT
DIABETES, VOL. 57, DECEMBER 2008 3343